TY - JOUR
T1 - Highlights of the first international "immunotherapy in pediatric oncology
T2 - Progress and challenges" meeting
AU - Capitini, Christian M.
AU - Cooper, Laurence J.N.
AU - Maarten Egeler, R.
AU - Handgretinger, Rupert
AU - Locatelli, Franco
AU - Sondel, Paul M.
AU - MacKall, Crystal L.
PY - 2009/4
Y1 - 2009/4
N2 - The first annual conference on immunotherapy in pediatric oncology was held in Bethesda, MD, from September 9 to 10, 2008 to discuss the state-of-the-art of immunotherapeutic strategies currently being explored in pediatric oncology. Major topics included targeting cell surface receptors, understanding and improving T-cell-based therapies, augmenting innate immune strategies, and enhancing graft-versus-leukemia for pediatric malignancies. As can be seen in the summaries of the individual presentations, significant progress has been made in developing preclinical models of pediatric tumors and a variety of novel immunobiologic therapies are approaching, or already in, the clinic. Although there is much excitement about the potential utility of these agents, a great deal of challenges lie ahead in improving the efficacy of each of these modalities and getting them to patients in a timely fashion. The resulting discussions will hopefully lead to new collaborations and insight for further translational and clinical studies.
AB - The first annual conference on immunotherapy in pediatric oncology was held in Bethesda, MD, from September 9 to 10, 2008 to discuss the state-of-the-art of immunotherapeutic strategies currently being explored in pediatric oncology. Major topics included targeting cell surface receptors, understanding and improving T-cell-based therapies, augmenting innate immune strategies, and enhancing graft-versus-leukemia for pediatric malignancies. As can be seen in the summaries of the individual presentations, significant progress has been made in developing preclinical models of pediatric tumors and a variety of novel immunobiologic therapies are approaching, or already in, the clinic. Although there is much excitement about the potential utility of these agents, a great deal of challenges lie ahead in improving the efficacy of each of these modalities and getting them to patients in a timely fashion. The resulting discussions will hopefully lead to new collaborations and insight for further translational and clinical studies.
KW - Cell surface receptors
KW - Graft-versus-leukemia
KW - Immunotherapy
KW - Innate immunity
KW - T cells
UR - http://www.scopus.com/inward/record.url?scp=65349125007&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65349125007&partnerID=8YFLogxK
U2 - 10.1097/MPH.0b013e31819a5d8d
DO - 10.1097/MPH.0b013e31819a5d8d
M3 - Article
C2 - 19346873
AN - SCOPUS:65349125007
SN - 1077-4114
VL - 31
SP - 227
EP - 244
JO - Journal of Pediatric Hematology/Oncology
JF - Journal of Pediatric Hematology/Oncology
IS - 4
ER -